Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates

SAN DIEGO, March 10, 2022 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced its financial results for the fourth quarter…

Click here to view original post